Natco Pharma Stock Screener | Share Price & Fundamental Analysis
NATCOPHARM
Pharmaceuticals
Screen Natco Pharma share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹925.90
▲
19.80 (2.19%)
Share Price BSE
₹926.20
▲
20.55 (2.27%)
Market Cap
₹15,922.87 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
1.87
EPS (TTM)
₹105.26
Dividend Yield
0.66%
Debt to Equity
0.05
52W High
₹1328.00
52W Low
₹746.50
Operating Margin
42.00%
Profit Margin
35.41%
Revenue (TTM)
₹1,463.00
EBITDA
₹679.00
Net Income
₹518.00
Total Assets
₹8,631.00
Total Equity
₹7,612.00
Natco Pharma Share Price History - Stock Screener Chart
Screen NATCOPHARM historical share price movements with interactive charts. Analyze price trends and patterns.
Natco Pharma Company Profile - Fundamental Screener
Screen Natco Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for NATCOPHARM shares.
Natco Pharma Limited is a vertically integrated pharmaceutical company specializing in the development, manufacturing, and marketing of Finished Dosage Formulations and Active Pharmaceutical Ingredients. The company focuses on niche therapeutic areas and complex products, selling in over 40 countries. Natco operates in the Pharmaceuticals and Agro chemicals segments, with nine manufacturing facilities across India and two research centers in Telangana. They engage in contract manufacturing and have capabilities in multi-step synthesis, semi-synthetic fusion technologies, high-potency APIs, and peptides. Natco has launched several generic versions of drugs in various markets and has expanded its product portfolio in oncology, cardiology, and diabetology. The company has multiple international subsidiaries and has made strategic acquisitions to strengthen its global presence.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
V C Nannapaneni
ISIN
INE987B01026
Website
https://www.natcopharma.co.in
Natco Pharma Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen NATCOPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 8,631 | 6,906 | 5,657 | 5,109 | 4,792 | 4,588 | 4,303 | 3,715 | 2,318 | 1,822 |
| Current Assets | 5,270 | 4,024 | 3,000 | 2,487 | 2,345 | 2,326 | 2,347 | 2,131 | 1,087 | 837 |
| Fixed Assets | 2,698 | 2,491 | 2,427 | 2,312 | 2,023 | 1,584 | 1,227 | 1,019 | 833 | 710 |
| Liabilities | ||||||||||
| Total Liabilities | 8,631 | 6,906 | 5,657 | 5,109 | 4,792 | 4,588 | 4,303 | 3,715 | 2,318 | 1,822 |
| Current Liabilities | 75 | 80 | 101 | 135 | 143 | 118 | 83 | 47 | 38 | 28 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 7,612 | 5,853 | 4,874 | 4,264 | 4,123 | 3,785 | 3,491 | 3,076 | 1,653 | 1,301 |
| Share Capital | 36 | 36 | 37 | 37 | 37 | 36 | 37 | 37 | 35 | 35 |
| Reserves & Surplus | 7,571 | 5,817 | 4,837 | 4,227 | 4,085 | 3,737 | 3,453 | 3,035 | 1,614 | 1,261 |
Screen NATCOPHARM income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,463 | 1,391 | 1,287 | 651 | 1,435 | 1,411 | 1,110 | 796 | 1,061 | 1,160 | 927 | 513 | 453 | 919 | 611 |
| Expenses | 784 | 758 | 673 | 436 | 567 | 558 | 571 | 491 | 573 | 613 | 559 | 387 | 337 | 489 | 615 |
| EBITDA | 679 | 633 | 614 | 215 | 868 | 853 | 539 | 305 | 487 | 548 | 368 | 127 | 116 | 430 | -5 |
| Operating Profit % | 42.00% | 43.00% | 45.00% | 8.00% | 59.00% | 59.00% | 47.00% | 35.00% | 44.00% | 46.00% | 38.00% | 22.00% | 22.00% | 45.00% | -3.00% |
| Depreciation | 52 | 58 | 98 | 47 | 46 | 44 | 56 | 44 | 44 | 44 | 41 | 42 | 42 | 40 | 38 |
| Interest | 13 | 3 | 10 | 4 | 4 | 5 | 6 | 5 | 4 | 4 | 3 | 4 | 4 | 4 | 7 |
| Profit Before Tax | 614 | 572 | 506 | 164 | 818 | 804 | 478 | 256 | 440 | 500 | 324 | 81 | 70 | 386 | -50 |
| Tax | 96 | 92 | 100 | 31 | 142 | 135 | 91 | 44 | 71 | 80 | 49 | 19 | 14 | 65 | 1 |
| Net Profit | 518 | 480 | 406 | 132 | 677 | 669 | 386 | 213 | 369 | 420 | 276 | 62 | 57 | 320 | -51 |
| EPS | 28.94 | 26.84 | 22.70 | 7.43 | 37.81 | 37.32 | 21.56 | 11.88 | 20.60 | 23.26 | 15.11 | 3.41 | 3.11 | 22.55 | -2.77 |
Natco Pharma Cash Flow Screener - Liquidity Fundamentals
Screen NATCOPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,697 | 1,212 | 849 | 47 | 299 | 417 | 669 | 464 | 346 | 112 |
| Investing Activities | -1,437 | -1,026 | -465 | 4 | -107 | -175 | -611 | -1,116 | -299 | -176 |
| Financing Activities | -211 | -247 | -363 | 35 | -186 | -251 | -51 | 651 | -48 | 154 |
| Net Cash Flow | 50 | -62 | 21 | 85 | 6 | -9 | 7 | -2 | -1 | 90 |
Screen NATCOPHARM shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 49.56% | 49.56% | 49.48% | 49.71% | 49.71% | 49.62% | 49.62% | 48.84% |
| FII Holding | 17.49% | 15.51% | 14.09% | 16.14% | 17.45% | 17.51% | 17.94% | 0.00% |
| DII Holding | 5.65% | 5.82% | 5.87% | 9.70% | 7.87% | 6.75% | 5.57% | 15.38% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 23.68% | 25.22% | 25.84% | 20.60% | 21.59% | 22.60% | 23.34% | 20.24% |
| Other Holding | 3.61% | 3.89% | 4.72% | 3.85% | 3.39% | 3.52% | 3.53% | 15.54% |
| Shareholder Count | 405,222 | 429,434 | 419,699 | 228,467 | 251,485 | 302,944 | 345,332 | 153,663 |
Natco Pharma Dividend Screener - Share Yield Analysis
Screen NATCOPHARM dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹6.00 | 0.66% |
| 2024-March | ₹9.50 | 1.19% |
| 2023-March | ₹5.50 | 0.58% |
| 2022-March | ₹4.50 | 0.81% |
| 2021-March | ₹5.25 | 0.69% |
| 2020-March | ₹6.75 | 0.82% |
| 2019-March | ₹6.25 | 1.24% |
| 2018-March | ₹8.25 | 1.44% |
| 2017-March | ₹6.75 | 0.90% |
Natco Pharma Index Membership - Market Screener Classification
Screen NATCOPHARM by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Natco Pharma Market Events Screener - Corporate Actions
Screen NATCOPHARM market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -0.11% | ||
| Annual General Meeting | NA | -3.48% | ||
| Annual General Meeting | NA | -1.94% | ||
| 2025-11-20 | 2025-11-20 | Dividend | ₹ 1.50 /share | 0.48% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 3.21% |
| 2025-08-19 | 2025-08-19 | Dividend | ₹ 2.00 /share | -2.87% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -2.84% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | 8.46% |
| 2025-02-18 | 2025-02-18 | Dividend | ₹ 1.50 /share | -29.89% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | 5.63% |
| 2024-11-27 | 2024-11-27 | Dividend | ₹ 1.50 /share | -2.91% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 8.04% |
| 2024-08-23 | 2024-08-23 | Dividend | ₹ 3.00 /share | 7.67% |
| 2024-02-26 | 2024-02-26 | Dividend | ₹ 1.25 /share | 19.93% |
| 2023-11-24 | 2023-11-24 | Dividend | ₹ 1.25 /share | -0.61% |
Natco Pharma Competitors Screener - Peer Comparison
Screen NATCOPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,638 | 39.35 | 54,729 | 9.71% | 10,980 | 38.94 |
| Divis Laboratories | 168,201 | 68.31 | 9,712 | 18.67% | 2,191 | 47.61 |
| Torrent Pharmaceuticals | 130,224 | 60.76 | 11,539 | 6.99% | 1,911 | 63.27 |
| Cipla | 121,303 | 22.46 | 28,410 | 7.12% | 5,291 | 50.85 |
| Dr Reddys Laboratories | 104,679 | 18.49 | 33,741 | 16.73% | 5,725 | 53.02 |
| Lupin | 96,115 | 22.19 | 22,910 | 13.74% | 3,306 | 57.47 |
| Zydus Life Science | 92,186 | 18.30 | 23,511 | 18.55% | 4,615 | 43.59 |
| Mankind Pharma | 89,698 | 51.11 | 12,744 | 20.90% | 2,007 | 49.10 |
| Aurobindo Pharma | 69,156 | 20.05 | 32,346 | 9.43% | 3,484 | 45.26 |
| Alkem Laboratories | 65,330 | 27.31 | 13,458 | 3.70% | 2,216 | 41.76 |
Natco Pharma Company Announcements - News Screener
Screen NATCOPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-03 | Closure of Trading Window | View |
| 2025-12-02 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-11-29 | Announcement under Regulation 30 (LODR)-Credit Rating | View |
| 2025-11-21 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-20 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-14 | Corporate Action-Board approves Dividend | View |
| 2025-11-14 | Financial Results For The Quarter And Half Year Ended 30Th September 2025 | View |
| 2025-11-14 | Record Date For Payment Of 2Nd Interim Dividend For The FY 2025-26 | View |
| 2025-11-14 | Board Meeting Outcome for Outcome Of Board Meeting | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-07 | Board Meeting Intimation for Considering And Approve The Financial Results For The Period Ended September 30 2025 And 2Nd Interim Dividend For The Financial Year Ending 2025-26 | View |
| 2025-10-31 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-10-17 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-10-10 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-10-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |